Polyphor AG POLN.SW · Stock Open Polyphor AG in new tab
Polyphor AG Analysis (POLN.SW)
Is Polyphor AG a good investment? Polyphor AG (POLN.SW) is currently trading at 1.67 CHF.
Investor FAQ
Does Polyphor AG pay a dividend?
No, it does not currently pay a dividend.
What asset class is Polyphor AG?
Polyphor AG is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
Company Profile
Polyphor AG, a clinical stage biopharmaceutical company, focuses on developing macrocycle drugs for cancer. Its lead drug candidates include Balixafortide (POL6326), an antagonist of the chemokine receptor CXCR4, which is in Phase III for combination treatment in oncology; POL6014, an inhaled inhibitor of neutrophil elastase, which is in Phase Ib clinical trial for the treatment of cystic fibrosis and other neutrophilic lung diseases; and outer membrane protein targeting antibiotics (OMPTA) platform. The company is also developing POL7306, targeting the most resistant MDR strains of all Gram-negative ESKAPE, including enterococcus faecium, staphylococcus aureus, klebsiella pneumoniae, acinetobacter baumannii, pseudomonas aeruginosa, and enterobacter species pathogens; and inhaled murepavadin (POL7080), a precision outer membrane protein targeting antibiotic for the treatment of pseudomonas aeruginosa. Polyphor AG was founded in 1996 and is headquartered in Allschwil, Switzerland.
Community Discussion